deltatrials
Completed PHASE2 NCT00133380

A Study in People With High Cholesterol

PPAR Alpha (LY518674): A Phase 2 Study of the Combinatorial Effect of LY518674 and Atorvastatin in Subjects With Hypercholesterolemia

Sponsor: Eli Lilly and Company

Conditions Hypercholesterolemia
Interventions PPAR alpha atorvastatin placebo
Updated 5 times since 2017 Last updated: Apr 4, 2007 Started: Jul 31, 2005 Completion: Sep 30, 2006

This PHASE2 trial investigates Hypercholesterolemia and is currently completed. Eli Lilly and Company leads this study, which shows 5 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Jul 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Eli Lilly and Company
Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Auburn, United States, Benzonia, United States, Brandon, United States, Bristol, United States, Cadillac, United States, Charlotte, United States, Chicago, United States, Excelsior Springs, United States, Fayetteville, United States, Greensboro, United States and 18 more location s